AstraZeneca Crestor delay
AstraZeneca expects an "approvable" letter for cholesterol agent Crestor (rosuvastatin) at the end of June, consistent with a 12-month user fee deadline, rather than original 10-month expectation. FDA is seeking data and analyses "to support the use of Crestor at higher doses," company says. The 80 mg dose was associated with rhabdomyolysis in Phase III trials (1"The Pink Sheet" Feb. 4, p. 25). The launch will be delayed beyond the third quarter...
You may also be interested in...
AstraZeneca expects that an 80 mg strength of Crestor, if approved, would constitute a small proportion of the product's sales
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.